Welcome to our dedicated page for Krystal Biotech news (Ticker: KRYS), a resource for investors and traders seeking the latest updates and insights on Krystal Biotech stock.
Krystal Biotech reports news on its commercial genetic-medicines business, led by VYJUVEK, a redosable gene therapy approved in the United States, Europe, and Japan for dystrophic epidermolysis bullosa. Company updates commonly cover VYJUVEK revenue and global commercialization, manufacturing and platform developments, and regulatory actions tied to its HSV-1-based gene delivery technology.
Recurring clinical and scientific updates address investigational programs including KB407 for cystic fibrosis, KB707 for advanced or metastatic non-small cell lung cancer, KB111 for Hailey-Hailey disease, KB803 for corneal abrasions in DEB patients, and additional HSV-1-based vectors. News also includes quarterly operating results, conference presentations, FDA designations, and investor-event participation.
Krystal Biotech (NASDAQ: KRYS) has announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024, in Miami. CEO Krish S. Krishnan will participate in a fireside chat at 10:40 am ET and host investor meetings throughout the day. A webcast of the presentation will be available on the company's website.
Krystal Biotech (NASDAQ: KRYS), a commercial-stage biotechnology company, announced its participation in the American Thoracic Society (ATS) 2024 International Conference from May 17-22 in San Diego, CA. The company will present new preclinical data on respiratory genetic medicine candidates KB407 and KB408. Both are modified, replication-defective, non-integrating HSV-1 vectors designed for inhaled lung delivery via nebulization. KB407 aims to treat cystic fibrosis, while KB408 targets alpha-1 antitrypsin deficiency. Data on these candidates will be shared, including insights from ongoing Phase 1 studies. Poster presentations by Dr. Sara Artusi will provide further details.
Krystal Biotech, Inc. (NASDAQ: KRYS) will participate in the BofA Securities 2024 Health Care Conference where Chairman and CEO Krish S. Krishnan will engage in a fireside chat and host investor meetings. The webcast of the presentation will be available on the Company's website.
Krystal Biotech, Inc. reported $45.3 million in net product revenue for 1Q 2024. The company is focused on delivering genetic medicines for rare diseases like Dystrophic Epidermolysis Bullosa. With a strong financial position and positive performance in clinical trials, Krystal Biotech is poised for growth. Key developments include progress with VYJUVEK, successful clinical studies in Japan, and ongoing trials for cystic fibrosis and alpha-1 antitrypsin deficiency treatments. The company also received FDA Fast Track Designation for inhaled KB707 for lung tumors. Financially, the company recorded $622.3 million in cash and investments with a net income of $0.9 million for 1Q 2024.
Krystal Biotech announced their participation in the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting where they will present new preclinical data on their HSV-1 based vector platform for back of the eye gene delivery. The poster presentation will focus on localized delivery to the posterior of the eye, with details about the presenter, date, time, and abstract number. The poster will be available both at the conference and online on the Investor section of the Company's website.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.